Y. Tomita

发表

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

B. Rini, V. Master, R. Uzzo, 2022, The Lancet.

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.

Jun Yu Li, J. Witjes, M. Galsky, 2023, European urology.

Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.

Y. Tomita, M. Takeda, M. Kimura, 1995, British Journal of Cancer.

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.

S. Naito, H. Fujimoto, N. Masumori, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

M. Oya, K. Tatsugami, Yoshihiko Tomita, 2023, International Journal of Clinical Oncology.

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

C. Porta, M. Burotto, R. Motzer, 2022, Cancer.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

C. Porta, M. Burotto, R. Motzer, 2022, The Lancet. Oncology.

Clinical Practice Guidelines for tuberous sclerosis complex‐associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update

M. Oya, Haruna Kawano, Yoshihiko Tomita, 2023, International journal of urology : official journal of the Japanese Urological Association.

Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study

Yoshihiko Tomita, N. Nonomura, R. Mizuno, 2022, International Journal of Clinical Oncology.

Advanced Bladder Cancer: Changing the Treatment Landscape

V. Bilim, Yoshihiko Tomita, Masaki Murata, 2022, Journal of personalized medicine.

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

R. Motzer, B. Escudier, A. Shah, 2024, ESMO open.

Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

C. Porta, M. Burotto, R. Motzer, 2022, Journal of Clinical Oncology.

Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells

V. Bilim, Yoshihiko Tomita, Masaki Murata, 2023, Current oncology.

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial

M. Galsky, D. Bajorin, M. Oya, 2022, Japanese journal of clinical oncology.

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

R. Motzer, M. Oya, Y. Tomita, 2017, Japanese journal of clinical oncology.

Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy

Yoshihiko Tomita, R. Ohashi, K. Yamana, 2022, Biomedicines.

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

M. Oya, M. Fujisawa, M. Shiota, 2023, Cancer Immunology, Immunotherapy.

Y. Tomita, S. Naito, Yoshihiko Tomita, 2014, Annals of Oncology.

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance

T. Nakao, Yoshihiko Tomita, N. Shinohara, 2022, International Journal of Clinical Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

S. Anai, M. Oya, Yoshihiko Tomita, 2022, Cancer medicine.

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

P. Russo, R. Motzer, B. Shuch, 2023, The Lancet.

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

C. Porta, M. Burotto, R. Motzer, 2023, Journal of Clinical Oncology.

Metastatic Renal Cell Carcinoma: Use of Bcl-2 and Fas to Predict Responses to Immunotherapy

V. Bilim, Y. Tomita, T. Itoi, 2010 .

Real‐world outcomes of avelumab plus axitinib as first‐line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J‐DART)

T. Miyagawa, N. Hinata, M. Nozawa, 2023, International journal of urology : official journal of the Japanese Urological Association.

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance

Takako Yamada, Yoshihiko Tomita, N. Shinohara, 2023, Japanese journal of clinical oncology.